Multiple sclerosis management has transformed significantly with modern disease-modifying agents. Today, clinicians utilize high-efficacy therapies to suppress clinical relapses and reduce acute focal inflammation. However, insidious neurodegeneration and subtle cognitive deterioration frequently persist beneath a stable clinical surface. Neurologists recognize that standard magnetic resonance imaging often fails to capture compartmentalized smoldering neuroinflammation. Consequently, identifying sensitive imaging biomarkers has become an urgent clinical priority. Recent evidence demonstrates that paramagnetic rim lesions serve as crucial determinants of cognitive trajectory. These specialized imaging markers reveal persistent microglial activation within the central nervous system. As a result, tracking paramagnetic rim lesions provides vital prognostic clarity for patients who appear clinically stable.

Understanding Paramagnetic Rim Lesions in Chronic MS Pathology

Paramagnetic rim lesions represent a distinct radiological hallmark of chronic active inflammation in multiple sclerosis. Histopathologically, these lesions feature a core of demyelinated tissue encircled by a peripheral rim of iron-laden microglia and macrophages. Consequently, this persistent cellular activity drives continuous, low-grade tissue destruction and axonal transection beyond the initial inflammatory attack. Standard T2-weighted or contrast-enhanced scans cannot distinguish these chronic smoldering areas because the blood-brain barrier remains largely intact. Therefore, advanced quantitative susceptibility mapping or susceptibility-weighted imaging is essential to visualize the paramagnetic phase shifts caused by iron deposition. Furthermore, clinical investigations confirm that chronic active lesions do not respond robustly to conventional peripheral immunomodulatory therapies. Because these lesions foster compartmentalized innate immune activation within the central nervous system parenchyma, they steadily expand over several years. As a result, patients experience progressive neurological disability and irreversible neuronal loss despite exhibiting no overt clinical relapses. Thus, recognizing the biology of paramagnetic rim lesions helps clinicians understand why some individuals experience silent disease progression while receiving potent therapeutic agents.

Evaluating Cognitive Trajectories Beyond Clinical Relapses

Cognitive impairment affects up to seventy percent of individuals living with multiple sclerosis. Specifically, processing speed, working memory, and executive function show marked vulnerabilities early in the disease course. Neurologists frequently employ the Symbol Digit Modalities Test to assess cognitive processing speed in routine clinical follow-ups. Although high-efficacy disease-modifying therapies successfully prevent overt physical relapses, cognitive outcomes remain remarkably variable among stable patients. Furthermore, traditional neurological assessments, such as the Expanded Disability Status Scale, predominantly measure ambulatory dysfunction and frequently miss subtle cognitive decline. Consequently, clinicians require precise longitudinal psychometric tracking to detect early neuroperformance changes. When investigators apply regression-based reliable change index methodology, they can reliably adjust for confounding variables like age, sex, and baseline education. This analytical approach enables clinicians to identify true cognitive deterioration versus expected practice effects across successive testing sessions. Therefore, objective cognitive monitoring illuminates the hidden burden of smoldering central nervous system pathology in relapse-free individuals.

Clinical Evidence on Paramagnetic Rim Lesions and Cognitive Decline

Recent prospective investigations provide compelling clinical evidence linking paramagnetic rim lesions to measurable cognitive decline. In a landmark longitudinal study, researchers followed ninety patients with relapsing-remitting multiple sclerosis who were treated with high-efficacy therapies over a twenty-four-month period. Notably, all enrolled patients remained entirely free of clinical relapses and demonstrated no new or gadolinium-enhancing T2 lesions on follow-up neuroimaging. Baseline magnetic resonance evaluations revealed that more than half of the cohort harbored paramagnetic rim lesions on quantitative susceptibility mapping. Multivariable regression analyses revealed that the presence of baseline rim lesions increased the risk of cognitive decline nearly fifteen-fold. Specifically, patients with these chronic active markers showed significant performance decreases on the Symbol Digit Modalities Test. In contrast, higher volumes of non-rim isointense lesions showed weak associations with cognitive preservation or mild improvement over time. Consequently, these robust findings underscore that compartmentalized inflammation actively drives cognitive deterioration even when high-efficacy therapies achieve apparent clinical and radiological remission.

Diagnostic Integration and Advanced Neuroimaging Protocols

Integrating advanced susceptibility sequences into routine clinical practice represents a major step forward for precision neurology. Magnetic resonance protocols utilizing quantitative susceptibility mapping, T2*-weighted sequences, or phase imaging reliably delineate the hypointense rims characteristic of persistent inflammation. Furthermore, modern diagnostic frameworks, including recent consensus guidelines, increasingly recognize chronic active lesions as pivotal biomarkers of disease severity. Clinicians should consider incorporating baseline susceptibility scans when initiating or switching high-efficacy therapies. Consequently, identifying these chronic inflammatory foci allows physicians to stratify patients based on their specific risk for silent neurodegeneration. In addition, routine neuroimaging should be paired with regular neurocognitive screening utilizing validated tools like the Symbol Digit Modalities Test. Because manual lesion identification can be time-consuming, automated artificial intelligence algorithms are emerging to accelerate lesion quantification. Therefore, adopting standardized neuroimaging workflows will facilitate early detection of smoldering pathology across diverse clinical settings.

Therapeutic Implications for Smoldering Neuroinflammation

The persistent activity of paramagnetic rim lesions highlights an urgent unmet need in contemporary neurotherapeutics. Although contemporary high-efficacy disease-modifying therapies excel at clearing peripheral circulating lymphocytes, they show limited efficacy against compartmentalized innate neuroinflammation within the parenchyma. Consequently, microglia trapped behind the blood-brain barrier continue to release neurotoxic factors, destroy oligodendrocytes, and perpetuate axonal loss. To combat this silent progression, pharmaceutical research is actively evaluating central nervous system-penetrant agents, including Bruton tyrosine kinase inhibitors. These novel small molecules cross the blood-brain barrier to modulate pathogenic microglia and potentially extinguish chronic rim activity. Furthermore, identifying patients with prominent rim lesions may guide clinicians toward earlier intervention with aggressive multimodal therapeutic strategies. In addition to pharmacological adjustments, clinicians should recommend cognitive rehabilitation and structured lifestyle interventions to bolster cognitive reserve. Ultimately, addressing compartmentalized smoldering inflammation represents the next frontier in preventing long-term disability for all individuals with multiple sclerosis.

Frequently Asked Questions

What are paramagnetic rim lesions in multiple sclerosis?

Paramagnetic rim lesions are specialized magnetic resonance imaging markers of chronic active lesions. They feature an active peripheral rim of iron-laden microglia and macrophages surrounding a demyelinated core. Consequently, these lesions reflect persistent, compartmentalized neuroinflammation and smoldering tissue destruction within the central nervous system parenchyma.

How does the Symbol Digit Modalities Test evaluate cognitive function?

The Symbol Digit Modalities Test is a brief, highly sensitive neuroperformance assessment that measures cognitive processing speed, visual scanning, and working memory. Patients pair specific numbers with corresponding geometric symbols under a timed protocol. Therefore, it provides clinicians with an objective metric to track subtle cognitive changes reliably over time.

Can patients experience cognitive decline without having clinical relapses?

Yes, patients with multiple sclerosis can experience insidious cognitive decline despite remaining completely relapse-free and stable on standard physical disability scales. This phenomenon occurs because compartmentalized smoldering inflammation and chronic active lesions continually drive subtle axonal loss, which standard clinical examinations and conventional imaging modalities often fail to detect.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Boccia VD et al. Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions. J Neurol Neurosurg Psychiatry. 2025 Jul 16. doi: 10.1136/jnnp-2024-335144. PMID: 39890460.
2. Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76(12):1474-1483. doi:10.1001/jamaneurol.2019.2399.
3. Cagol A, Cortese R, Barakovic M, et al. Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Lancet Neurol. 2024;23(8):821-834. doi:10.1016/S1474-4422(24)00213-9.
4. Meaton I, Altokhis A, Allen CM, et al. Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Mult Scler. 2022;28(14):2212-2220. doi:10.1177/13524585221123456.